CNS Pharmaceuticals, Inc. Notes Payable, Current
CNS Pharmaceuticals, Inc. (CNSP) had Notes Payable, Current of $0 as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:NotesPayableCurrent · last filed 2026-08-12
- 2026-06-30: Notes Payable, Current $0.00.
- 2026-03-31: Notes Payable, Current $232.35K.
- 2025-12-31: Notes Payable, Current $328.00K; Notes Payable, Current as first filed $328.57K.
- 2025-09-30: Notes Payable, Current $30.79K.
| Period end | Notes Payable, Current | Notes Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $232.35K 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $328.00K 10-Q · filed 2026-08-12 | $328.57K 10-K · filed 2026-03-31 |
| 2025-09-30 | $30.79K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $121.77K 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $210.67K 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $326.07K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $31.19K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $123.25K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $213.10K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $300.81K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $41.90K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $166.40K 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $289.07K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $409.97K 10-K · filed 2024-04-01 | |
| 2022-09-30 | $39.26K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $156.40K 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $272.57K 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $387.79K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $44.63K 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $177.58K 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $309.13K 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $439.29K 10-K · filed 2022-03-03 | |
| 2019-12-31 | $0.00 10-K · filed 2021-02-12 | |
| 2019-09-30 | $0.00 10-Q · filed 2019-12-20 | |
| 2018-12-31 | $35.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |